Efficacy of Vonoprazan-based triple therapy for cure of H. Pylori Infection among patients attending GIT outpatient clinic at Suez Canal University Hospital | ||
| Microbes and Infectious Diseases | ||
| Article 20, Volume 4, Issue 2, May 2023, Pages 506-513 PDF (616.5 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/mid.2023.191490.1459 | ||
| Authors | ||
| Nageh Louis Mahrous1; Eman Nasrelden2; Mariam Hassan* 3; Mohamed Aboelmagd1 | ||
| 1Endemic and Infectious diseases department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt | ||
| 2Internal Medicine Department, Faculty of Medicine, Suez Canal University ,Ismailia, Egypt | ||
| 3Gastroenterology and Hepatology department, Ahmed Maher Teaching Hospital | ||
| Abstract | ||
| Background: Treatment of Helicobacter pylori (H.pylori) became mandatory for prevention and cure of most upper gastrointestinal complaints. Despite the varieties in available therapeutic options, achieving a high eradication rate is very challenging. Currently, vonoprazan based protocols are being introduced, and they provide promising outcomes. We aimed at studying vonoprazan efficacy and safety for cure of H.pylori among Egyptian patients. Methods: In a prospective cohort study, we included 300 patients who tested positive for H. pylori to receive vonoprazan-based triple therapy for two weeks. Then, we assessed the cure rate, improvement of symptoms and side effects. Results: We found that vonoprazan-based triple therapy achieved a cure rate of 90%. There was a remarkable improvement in all presenting symptoms after complete cure with this regimen. Few adverse effects were observed, not exceeding 9.3% of patients. Most common side effects were nausea (4.3%), burping (2.6%) and bloating (1.3%). Conclusions: vonoprazan-based triple therapy is effective and safe for cure of Helicobacter. | ||
| Keywords | ||
| Vonoprazan; Helicobacter pylori; Triple therapy, Eradication, Cure | ||
|
Statistics Article View: 1,031 PDF Download: 431 |
||
